This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
3 MedTech Outperformers to Grab Amid September Pullback
by Trina Mukherjee
Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.
5 Top PEG-Driven Value Stocks Amid Coronavirus-Led Selloffs
by Urmimala Biswas
While searching for a suitable value investment option, investors are unlikely to consider PEG ratio among a number of other popular value metrics.
Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.
CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day
by Zacks Equity Research
CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day
3 MedTech Outperformers to Grab Amid Coronavirus Pandemic
by Trina Mukherjee
Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TVTY, NXGN, ELMD and FMS
Should Value Investors Buy Fresenius (FMS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FMS or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
FMS vs. SMLR: Which Stock Is the Better Value Option?
4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus
by Debanjana Dey
Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.
5 Best GARP Stocks Based on Discounted PEG
by Urmimala Biswas
There are some drawbacks to using the PEG ratio though. It does not consider the very common situation of changing growth rates.
Here's Why You Should Invest in Fresenius Medical Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services.
Is Fresenius (FMS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FMS or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
FMS vs. SMLR: Which Stock Is the Better Value Option?
3 Reasons Why Fresenius (FMS) Is a Great Growth Stock
by Zacks Equity Research
Fresenius (FMS) could produce exceptional returns because of its solid growth attributes.
New Strong Buy Stocks For August 18th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is Fresenius (FMS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FMS vs. SMLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FMS vs. SMLR: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Smurfit Kappa, Turning Point Brands, Griffon and Fresenius Medical Care
by Zacks Equity Research
Zacks.com featured highlights include: Smurfit Kappa, Turning Point Brands, Griffon and Fresenius Medical Care
Forget Profit, Bet on These 4 Stocks With Rising Cash Flows
by Moumita C. Chattopadhyay
Even though profit is a company's goal, cash is its lifeblood for existence and a measure of resiliency.
Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.
Looking for a Growth Stock? 3 Reasons Why Fresenius (FMS) is a Solid Choice
by Zacks Equity Research
Fresenius (FMS) could produce exceptional returns because of its solid growth attributes.
Idexx (IDXX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks For August 3rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Should Value Investors Buy Fresenius (FMS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FMS vs. ABMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
FMS vs. ABMD: Which Stock Is the Better Value Option?